Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD

 Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD

Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active UC or CD

Shots:

  • The CHMP’s positive opinion is based on P-III VISIBLE study assessing vedolizumab (SC) as maintenance therapy vs PBO in ~1000 patients with moderately to severely active UC & CD who achieved clinical response @6wks. following the 2doses of vedolizumab (IV) @0 & 2wks.
  • EC will now review the CHMP’s positive opinion and if approved, vedolizumab will be the only maintenance therapy for UC & CD with both IV & SC formulation in the EU
  • Vedolizumab SC is a gut-selective biologic act by inhibiting alpha4beta7 integrin binding to MAdCAM-1 and not VCAM-1 and is expected to be available in both pre-filled syringe and a pre-filled pen

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post